New Treatments in Melanoma

 

The aim of this evaluation form is to gain your feedback, in order to maintain high educational standards and provide a reference for continuous improvement. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did this E-Learning module provide an update on novel immunotherapies and targeted agents available for the treatment of patients with advanced melanoma, including associated biomarkers? (1-no, not at all; 5-yes, absolutely)

2. Did this E-Learning module provide an update on clinical results from recent randomised studies with immunotherapies and targeted agents in patients with advanced melanoma, including recommendation for a current therapeutic algorithm? (1-no, not at all; 5-yes, absolutely)

3. Did this E-Learning module provide insights on the profile of side-effects from novel immunotherapies and targeted agents available for the treatment of patients with advanced melanoma, including clinical guidance for their management? (1-no, not at all; 5-yes, absolutely)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-absolutely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. If you would like to add your personal comments or make suggestion to improve future ESMO E-Learning material, please write in the box below: